

Impression Files Patent over IHL-42X Drug for the Treatment of Obstructive Sleep Apnoea

Highlights:

- Patent filing over IHL-42X drug to be delivered to patient as a nocturnally administered pill
- Pill form treatment vastly less intrusive to the patient than existing conventional treatment method, the CPAP device
- CPAP device has a significant downside of patient non-compliance due to lack of comfort, disruption to partners, among other factors
- IHL to proceed with IHL-42X in-human observations under the guidance of the medical team, dosage studies, formulation refinement and other clinical activities following novel patent protection being lodged
- OSA is the second most diagnosed respiratory condition after asthma, making it the largest cause of chronic pathology for which no registered pharmacological treatment exists today
- Current global annual market size for OSA detection and treatment using CPAP devices is over US\$10B per annum and growing, indicating a substantial market for better OSA solutions.

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company'), developer of four unique medical cannabis products, owner of INCANNEX™ cannabis oils and oral devices manufacture, today announces that it has filed a patent application covering IHL-42X in pill form to be used in the treatment of Obstructive Sleep Apnoea ('OSA').

The patent filing follows extensive work undertaken by Impression's CMO Dr Sud Agarwal and Dr David Cunningham, who is a world recognised specialist sleep physician and member of the IHL medical advisory board.

Having the patent application in place facilitates the commencement of further work related to initial in-human observations, in-vivo studies, dosage studies, formulation refinement and other clinical activities in a manner that is now afforded initial patent protections.

Treatment of OSA with a pill taken nocturnally is considered highly desirable to patients and public health officials. OSA is the second most diagnosed respiratory condition after asthma, making it the largest cause of chronic pathology for which no registered pharmacological treatment exists today. Furthermore, OSA is currently under-treated due to high patient non-compliance with the CPAP device, which is the existing first-line treatment option for patients.

Dr Sud Agarwal, Chief Medical Officer and Non-executive Director of Impression, said, "Having the patent in place affords the Impression team the relevant protection it needs in the near term to push ahead with further development of IHL-42X."

ENDS



Date: 06th December 2019
ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited (IHL.ASX) is undertaking four clinical trials investigating the use of uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea, Traumatic Brain Injury/Concussion, Periodontitis (Gum Disease) and Temporomandibular Joint Disorder. Each indication represents major global markets.

IHL has its Australian licenses in place to import, export and distribute cannabis products and has launched a line of EU GMP-approved CBD oil products under the brand, "INCANNEX™". INCANNEX™ oils may be sold under IHL's product supply and distribution agreement with Cannvalate Pty Ltd – the largest network of cannabis medicine prescribers in Australia.

Providing growing revenues to the Company; Impression continues to build its customised oral devices manufacturing business both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network.

Investors: investors@impression.healthcare

Website: www.impression.healthcare